Legacy Capital Group California Inc. lessened its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 5.4% in the 3rd quarter, according to its most recent filing with the Securities & ...
International Assets Investment Management LLC purchased a new stake in Pfizer Inc. (NYSE:PFE – Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The firm ...
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.
The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...
GlobalData on MSN3d
FDA expands Pfizer’s RSV vaccine label to include all high-risk adultsAbrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback